

Carbapenem-Resistant Enterobacteriaceae Colonization or Infection Was Not Associated with Post-Liver Transplant Graft Failure: An Observational Cohort Study

João Caria^a Ana C. Gonçalves^a Gonçalo Cristóvão^a Maria Carlos^a
Sara Magalhães^a Vasco Almeida^a Fernanda Moreno^b Élia Mateus^b
Hélder Pinheiro^a Diana Póvoas^a Fernando M.T. Maltez^a Rui Perdigoto^c
Filipe S. Cardoso^c Hugo P. Marques^c

^aInfectious Diseases Division, Curry Cabral Hospital, Lisbon, Portugal; ^bTransplant Unit, Curry Cabral Hospital, Lisbon, Portugal; ^cTransplant Unit, Curry Cabral Hospital, Nova Medical School, Lisbon, Portugal

Keywords

Carbapenem · Multidrug resistance · Colonization · Infection · Liver transplantation

Abstract

Introduction: Carbapenem-resistant Enterobacteriaceae (CRE) epidemiology among liver transplant (LT) recipients is variable. We studied the impact of CRE colonization and infection on LT recipients' outcomes. **Methods:** This observational cohort study included consecutive adult LT recipients between January 2019 and December 2020 at Curry Cabral Hospital, Lisbon, Portugal. Primary exposures were CRE colonization (rectal swabs under a screening program) and infection within 1 year of index LT. Primary endpoint was graft failure within 1 year of the index LT. **Results:** Among 209 patients, the median (interquartile range [IQR]) age was 57 (47–64) years and 155 (74.2%) were male. CRE colonization was identified in 28 (13.4%) patients during the first year posttransplant (median [IQR] number of rectal swabs per patient of 4 [2–7]). CRE resistance genes identified were OXA48 in 8 (3.6%) patients, KPC in 19 (67.9%) patients, and VIM in 1 (3.6%) patient. Any

bacterial/fungal and CRE infections were diagnosed in 88 (42.1%) and 6 (2.9%) patients, respectively, during the first year posttransplant. After adjusting for confounders, neither CRE colonization (aOR [95% CI] = 1.83 [0.71–4.70]; $p = 0.21$) nor infection (aOR [95% CI] = 1.35 [0.17–11.06]; $p = 0.78$) was associated with graft failure within 1 year of index LT. **Discussion/Conclusion:** Under a screening program, CRE colonization and infection prevalence was low and neither was associated with graft failure.

© 2024 The Author(s).
Published by S. Karger AG, Basel

Colonização ou infecção por Enterobacteriaceae resistentes a carbapenemos não se associaram a falência do enxerto pós-transplante de fígado: um coorte observacional

Palavras Chave

Carbapenem · Multirresistência · Colonização · Infecção · Transplante de fígado

Filipe S. Cardoso and Hugo P. Marques share senior authorship.

Resumo

Introdução: A epidemiologia de Enterobacteriaceae resistentes a carbapenemos (CRE) entre receptores de transplante hepático (TH) é variável. Estudámos o impacto da colonização e da infecção por CRE nos resultados dos receptores de TH. **Métodos:** Estudo coorte observacional incluindo adultos consecutivos receptores de TH entre Janeiro de 2019 e Dezembro de 2020 no Hospital Curry Cabral, Lisboa, Portugal. As exposições primárias foram colonização por CRE (esfregaços retais sob programa de rastreio) e infecção dentro de um ano após o TH índice. O resultado primário foi a falência do enxerto dentro de um ano após o TH índice. **Resultados:** Entre 209 doentes, a idade mediana (IQR) foi de 57 (47–64) anos e 155 (74.2%) eram do sexo masculino. A colonização por CRE foi identificada em 28 (13.4%) doentes durante o primeiro ano após o TH (número mediano (IQR) de esfregaços retais por paciente de 4 [2–7]). Os genes de resistência CRE identificados foram: OXA48 em 8 (3.6%), KPC em 19 (67.9%) e VIM em 1 (3.6%) doente. Infecções a qualquer microrganismo e CRE foram diagnosticadas em 88 (42.1%) e 6 (2.9%) doentes, respectivamente, durante o primeiro ano após o transplante. Após ajuste para fatores de confusão, nem colonização (aOR [95% CI] = 1.83 [0.71–4.70]; $p = 0.21$) nem infecção por CRE (aOR [95% CI] = 1.35 [0.17–11.06]; $p = 0.78$) se associaram com falência do enxerto dentro de um ano após TH índice. **Discussão/Conclusões:** No âmbito de um programa de rastreio, a prevalência de colonização e infecção por CRE foi baixa e nenhuma delas se associou com falência do enxerto após TH.

© 2024 The Author(s).
Published by S. Karger AG, Basel

Introduction

Infection still represents the main cause of graft failure within 1 year of liver transplant (LT), despite improvements in the surgical technique, organ support, infection control, and immunosuppression regimens [1]. Nosocomial infection, occurring mainly in the first month after LT, may contribute further to morbidity and mortality [1]. The rising prevalence of multidrug-resistant microorganisms (MDRs) worldwide may make it more difficult to treat nosocomial infections, as effective antimicrobials remain limited [2]. Strategies to prevent infections from such difficult-to-treat microorganisms frequently include institutional protocols for colonization studies.

Factors such as cirrhosis-related gut dysbiosis, exposure to prolonged courses of antimicrobials, or post-LT complications may increase the risk of MDR colonization among LT recipients [3]. Colonization with methicillin-resistant *Staphylococcus aureus* or vancomycin-resistant *Enterococcus faecium* has been associated with a higher risk of infections among LT recipients [4, 5]. The impact of carbapenem-resistant Enterobacteriaceae (CRE) colonization on the outcomes of LT recipients has been poorly studied [6, 7]. Accordingly, we hypothesized that CRE colonization may negatively impact these patients' outcomes. Therefore, this study's objectives were the following: (1) determine the prevalence of CRE colonization and infection among LT recipients; (2) study the association between CRE colonization and infection with clinical outcomes.

Materials and Methods

Ethics

The Central Lisbon University Hospital Center (CLUHC) Ethics Committee approved the study's protocol and waived the individual informed consent due to its observational character (INV_447). The study's conduct followed the principles of the Declaration of Helsinki [8]. The study's reporting followed the STROBE guideline [9].

Design, Setting, and Participants

This observational retrospective cohort study included all adult (age ≥ 18 years) patients who underwent LT between January 2019 and December 2020 at Curry Cabral Hospital (CCH), CLUHC.

Definitions, Exposures, and Endpoints

Since 2018, there has been a prospective CRE surveillance protocol in the Transplant Unit at CCH as a tool to prevent cross-contamination among patients in the ward. All patients admitted for LT, whether elective (in the ward) or urgent (in the ICU), performed the first CRE rectal swab < 24 h before transplantation. All patients who underwent LT were admitted to the ICU after the surgery. Following that index swab, patients were due to repeat the CRE rectal swab before ICU discharge to the ward or weekly until hospital discharge.

The CRE rectal swab was performed by the nursing staff using a specified kit (COPAN®): the humid swab was rubbed (360° movement) in the patients' anal canal, stored in a predefined involucrum, and sent within 2 h to the CCH laboratory. Afterward, a real-time polymerase chain reaction test was performed to search for 4 genes associated with carbapenemases' production by Gram-negative bacteria in the gut (GeneXpert®, Cepheid®): OXA48, KPC, NDM, or VIM (the IMP1 gene was only added after the study's inclusion period, so it was not considered) [10, 11].

Patients with a CRE-positive rectal swab were placed under contact precautions in a single room or were positioned within a CRE-positive ward cohort, including patients with the same colonizing gene. Contact precautions ceased only once there were

2 consecutive (1 week apart at least) negative rectal swabs. Overall, the following patients' data were collected from their electronic records: age, sex, LT indication, site before LT, urgent LT, comorbidities pre-LT, disease severity scores (model for end-stage liver disease with sodium correction [MELDNa] and Sequential Organ Failure Assessment [SOFA]), immunosuppression post-LT (the local protocol is detailed in online suppl. Table S1; for all online suppl. material, see <https://doi.org/10.1159/000539690>), body fluids' cultures (blood, urine, ascites, or bile as in online suppl. Table S2), and cytomegalovirus (CMV) serum viral loads (quantification limit of 34.5×10^7 UI/mL) requested at clinicians' discretion, known standard risk factors for MDR colonization or infection (hospital stay, MDR colonization or infection, and antibiotics) within 1 year prior to the index hospital admission, and CRE colonization and infection within 1 year following the index LT.

The standard LT antibiotic prophylaxis at CCH was cefotaxime (1 g every 8 h) and ampicillin (2 g every 6 h) for 24 h. There was no decontamination strategy in place for CRE-colonized patients. CRE infection empirical antimicrobial therapy was at clinicians' discretion based on local antibiograms. Antimicrobial therapy was then adjusted at the earliest possible time based on available sensitivity tests.

Primary exposures were CRE colonization and infection within 1 year of index LT. Primary endpoint was graft failure within 1 year of the index LT. This endpoint was selected to better characterize both organs' and patients' morbidity and mortality during the first year post-LT. Additional outcomes considered were all-cause mortality within 1 year of the index LT and index ICU and hospital length of stay. The follow-up time period ended in October 2022.

Statistical Analyses

Descriptive analysis used absolute frequency (%) and median (interquartile range [IQR]) for categorical or continuous variables, respectively. Missing data across all variables were 0.2%, and no multiple imputation was performed.

Univariable comparisons used the χ^2 or Mann-Whitney tests where appropriate. Adjusted associations between CRE colonization or infection and graft failure within 1 year of index LT were studied using logistic regression. Variables were initially included in the models if deemed clinically significant and with a $p < 0.10$ on univariable analysis. A stepwise backward selection process was applied to build the final models. To avoid overfitting, the number of covariables admitted was restricted to one covariable per 10 events. The models' fitness was assessed using the χ^2 test. Statistical significance was defined by $p < 0.05$ (2-tailed). IBM SPSS Statistics (version 28.0; IBM Corp, Armonk, NY, USA) was used for all statistical analyses.

Results

Baseline Characteristics

Between January 2019 and December 2020, there were 239 LT procedures performed in 209 patients at CCH. Thus, there were 30 retransplants during this time period (25 within 1 year of index LT).

Median (IQR) age was 57 (47–64) years, and 155 (74.2%) patients were males. Cirrhosis and hepatocellular carcinoma were the leading causes of LT in 106 (50.7%) and 61 (29.2%) patients, respectively (Table 1). Etiologies of cirrhosis in the absence of hepatocellular carcinoma are presented in online supplementary Figure S1. Elective LT was performed in 175 (83.7%) patients.

Median (IQR) MELDNa pre-LT and SOFA scores upon the end of LT surgery were 15 (12–21) and 6 (4–8), respectively. Immunosuppression induction with basiliximab (antagonist of IL2 receptor) was used in 127 (60.8%) patients. All baseline characteristics are depicted in Table 1.

Exposures and Endpoints

Overall, risk factors for MDR colonization or infection identified within 1 year prior to LT were the following: previous hospital stay in 114 (54.5%), MDR colonization in 6 (2.9%), MDR infection in 13 (6.2%), and antibiotics use in 54 (26.0%) patients (Table 1). With the CRE surveillance program at CCH, 28 (13.4%) patients who underwent LT were diagnosed with CRE colonization during the first year posttransplant. During that time period, the median (IQR) number of CRE rectal swabs performed per patient was 4 (2–7). Moreover, the median (IQR) time to CRE positive rectal swab was 17 (5–39) days post-LT; in fact, 6 (21.4%) patients had a positive test since the day of index LT.

The following CRE resistance genes were identified: OXA48 in 8 (3.6%) patients, KPC in 19 patients (67.9%), and VIM in 1 (3.6%) patient. The NDM gene was not identified in this cohort. Only 1 patient showed colonization with 2 different CRE genes (OXA48 and KPC, with 98 days of interval). Among the 28 patients with CRE colonization, 6 (21.4%) eventually had at least 2 consecutive negative rectal swabs during the follow-up time period. The median (IQR) time between the first positive and negative CRE rectal swabs was 213 (82–530) days.

During the first year post-LT, any bacterial/fungal and CRE infections were diagnosed in 88 (42.1%) and 6 (2.9%) patients, respectively. Abdominal and bloodstream infections accounted for 33.9% (38/112) and 27.7% (31/112) of all diagnosed infections, respectively. The foci of these infections are detailed in online supplementary Table S3. The most prevalent bacteria causing these infections were *Klebsiella pneumoniae* (17.4%), *Enterococcus faecium* (12.8%), and *Escherichia coli* (10.5%). Among CRE infections, 4 were bloodstream infections, one was pneumonia, and another one was a urinary tract infection. Among fungal infections, 5

Table 1. Baseline characteristics of patients who underwent liver transplantation from January 2019 to December 2020 stratified by 1-year post-liver transplantation graft failure

Characteristic (n [%] or median [IQR])	N total = 209 (100%)	N graft failure at 1-year post-LT = 45 (21.5%)	N graft viable at 1-year post-LT = 164 (78.5%)	p value
Age, years	57 (47–64)	52 (46–62)	58 (46–64)	0.20
Sex, male	155 (74.2%)	32 (71.1%)	123 (75.0%)	0.60
LT indication, n (%)	–	–	–	0.86
ALF	10 (4.8)	2 (4.4)	8 (4.9)	–
Cirrhosis*	106 (50.7)	25 (55.6)	81 (49.4)	–
HCC	61 (29.2)	10 (22.2)	51 (31.1)	–
ColangioCa	3 (1.4)	1 (2.2)	2 (1.2)	–
Retransplant	19 (9.1)	4 (8.9)	15 (9.1)	–
FAP	10 (4.8)	3 (6.7)	7 (4.3)	–
Site before LT, n (%)	–	–	–	0.032
Home	164 (78.5)	34 (75.6)	130 (79.3)	
Ward	30 (14.4)	4 (8.9)	26 (15.9)	
ICU	15 (7.2)	7 (15.6)	8 (4.9)	
Urgent LT	34 (16.3)	9 (20.0)	25 (15.2)	0.44
Comorbidities pre-LT, n (%)				
CKD	17 (8.1)	8 (17.8)	9 (5.5)	0.008
Diabetes	60 (28.7)	13 (28.9)	47 (28.7)	0.98
HIV infection	2 (1.0)	0 (0)	2 (1.2)	0.99
Malignancy	87 (41.6)	18 (40.0)	69 (42.0)	0.80
MELDNa pre-LT (n = 208)	15 (12–21)	15 (11–26)	16 (12–20)	0.94
SOFA post-LT	6 (4–8)	8 (3–14)	5 (4–7)	0.005
Basiliximab induction, n (%)	127 (60.8)	30 (66.7)	97 (59.1)	0.36
CMV reactivation post-LT, n (%)	6 (2.9)	4 (8.9)	2 (1.2)	0.020
Standard risk factors for MDR colonization/infection (1-year pre-LT), n (%)				
Hospital stay	114 (54.5)	28 (62.2)	86 (52.4)	0.24
MDR colonization	6 (2.9)	2 (4.4)	4 (2.4)	0.61
MDR infection	13 (6.2)	3 (6.7)	10 (6.1)	0.99
Antibiotics	54 (26.0)	14 (31.1)	40 (24.5)	0.37
CRE colonization/infection (1-year post-LT)				
N swabs during follow-up	4 (2–7)	4 (1–9)	3 (2–6)	0.61
Time to positive swab since LT, days	17 (5–39)	28 (0–65)	14 (6–35)	0.75
CRE colonization, n (%)	28 (13.4)	9 (20.0)	19 (11.6)	0.14
Any bacterial/fungal infection (n = 206), n (%)	88 (42.1)	21 (48.8)	67 (40.9)	0.32
CRE infection (n = 207), n (%)	6 (2.9)	2 (4.7)	4 (2.4)	0.44
Index LT hospital stay duration				
ICU LOS	4 (3–8)	7 (2–13)	4 (3–6)	0.12
Hospital LOS	20 (14–34)	24 (12–37)	20 (14–33)	0.83

LT, liver transplantation; ALF, acute liver failure; HCC, hepatocellular carcinoma; ACLF, acute-on-chronic liver failure; ColangioCa, cholangiocarcinoma; FAP, familial amyloid polyneuropathy; ICU, intensive care unit; CKD, chronic kidney disease; HIV, human immunodeficiency virus; MELDNa, model for end-stage liver disease with sodium correction score; SOFA, Sequential Organ Failure Assessment score; OR, operating room; CMV, cytomegalovirus; MDR, multidrug-resistant microorganism; CRE, carbapenemases producing Gram-negative bacteria; LOS, length of stay. *Among 106 cirrhosis patients, 6 had ACLF (2.9%) and 5 had graft failure at 1-year post-index LT.

Candida spp. isolates (5.9%) were identified – 3 causing cholangitis, one peritonitis, and another one a bloodstream infection. A complete list of microorganisms isolated is

depicted in online supplementary Table S4. Finally, CMV reactivation was detected in 6 (2.9%) patients during the first year post-index LT.

Table 2. Logistic regression multivariable associations between carbapenemase-producing bacteria colonization and 1-year post-liver transplantation graft failure

Covariable	OR (95% CI)	p value
Model 1		
ICU at LT	2.11 (0.61–7.33)	0.24
CKD pre-LT	2.50 (0.81–7.73)	0.11
SOFA post-LT	1.13 (1.05–1.23)	0.002
CRE colonization	1.83 (0.71–4.70)	0.21
Model 2		
ICU at LT	2.36 (0.70–7.96)	0.17
CKD pre-LT	2.48 (0.79–7.84)	0.12
SOFA post-LT	1.12 (1.03–1.21)	0.011
CRE infection	1.35 (0.17–11.06)	0.78

OR, odds ratio; CI, confidence interval; ICU, intensive care unit; LT, liver transplantation; CKD, chronic kidney disease; SOFA, Sequential Organ Failure Assessment score; CRE, carbapenemases producing Gram-negative bacteria. Model 1: n total = 209, n events = 45, $p < 0.001$. Model 2: n total = 207, n events = 43, $p = 0.002$.

MDR colonization (14.3 vs. 1.1%; $p = 0.003$) or infection (17.9 vs. 4.4%; $p = 0.006$) within 1 year prior to LT was associated with a higher frequency of CRE colonization 1-year post-LT. Also, MDR colonization (33.3 vs. 2.0%; $p = 0.010$) within 1 year prior to LT was associated with a higher frequency of CRE infection 1-year post-LT, but MDR infection prior to LT was not (16.7 vs. 6.0%; $p = 0.33$).

Among all patients included, 26 (12.4%) died within 1 year of LT. Furthermore, 19 (9.1%) required a retransplant but survived that same time period. Therefore, graft failure within 1 year of index LT was 21.5% (45/209 patients). Median (IQR) index ICU and hospital length of stay were 4 (3–8) and 20 (14–34) days, respectively. Overall, the median (IQR) follow-up time period post-index LT was 1,079 (859–1,236) days. All exposures and endpoints are detailed in Table 1.

Association of CRE Colonization and Infection with Graft Failure

Based on univariable comparisons, patients with CRE colonization were more likely to develop any bacterial/fungal (20.5 vs. 8.3%; $p = 0.011$) or CRE (83.3 vs. 11.4%; $p < 0.001$) infections during the first year post-LT than non-colonized ones. Furthermore, patients with graft failure within 1 year of index LT were more likely on ICU before LT (15.6 vs. 4.9%; $p = 0.032$), had more often CKD pre-LT (17.8 vs. 5.5%; $p = 0.008$), had a higher median SOFA score posttransplant surgery (8 vs. 5; $p = 0.005$), had more often

positive blood cultures in the OR (24.4 vs. 7.9%; $p = 0.002$), and had more often CMV reactivation during the first year post-LT (8.9 vs. 1.2%; $p = 0.020$) than those alive without retransplant (Table 1).

Based on multivariable logistic regression, after adjusting for significant confounders, namely, ICU at LT, CKD pre-LT, and SOFA score post-LT, CRE colonization was not associated with graft failure within 1 year of index LT (Table 2: model 1: adjusted odds ratio (aOR) [95% CI] = 1.83 [0.71–4.70]; $p = 0.21$). In a similar adjusted analysis, CRE infection was also not associated with graft failure within 1 year of index LT (aOR [95% CI] = 1.35 [0.17–11.06]; $p = 0.78$).

Discussion

Main Findings and Comparisons with Previous Literature

In a large Portuguese cohort of LT recipients subjected to a standardized protocol of CRE screening, CRE colonization and infection rates within 1 year of index transplant were 13.4% and 2.9%, respectively. In an Italian cohort of 553 LT recipients, CRE colonization and infection rates were 25.7% and 10.3%, respectively, figures higher than what has been observed in our cohort [7]. Both country-level and institutional-level features may help explain such differences. While overall CRE prevalence may vary widely with geography, Portugal has been experiencing outbreaks, but rates reported have been lower than in neighboring Southern European countries, such as Spain, Italy, or Greece [10, 11]. Additionally, at our center, strict contact precautions have been enforced in the ICU and ward to help mitigate the risk of cross-contamination among admitted patients. Thus, we speculate that CRE colonization rates may have also benefited from this strict institutional policy.

We also found that CRE-colonized patients were more likely to develop any bacterial/fungal or CRE infections than non-colonized ones during the follow-up period. Previous literature reported on the association between CRE colonization and infection [7, 12]. In fact, post-LT complications, such as biliary leaks or strictures, with often difficult source control and requiring prolonged courses of antimicrobials, as well as multiple-week hospital stays, may create the ideal environment for CRE infection, especially in previously colonized patients. Given the small number of patients with CRE colonization prior to LT, we could not address the association between colonization at such timing and post-LT outcomes. Interestingly, not all CRE-colonized patients ended up developing an infection; therefore the

colonization-infection relationship is far more complex than may be clinically perceived. Among other factors, post-LT evolving gut dysbiosis may play a role in this pathophysiological process [3, 12]. Namely, factors such as gut inflammation related to surgery or critical illness, antimicrobials' pressure, or immunosuppression effects may all contribute to altering the gut microbiome.

In our cohort, almost two-thirds of LT recipients got induction immunosuppression with an anti-IL2 drug (basiliximab) and steroids; following that, almost all patients required maintenance immunosuppression with a calcineurin inhibitor (mostly tacrolimus) and steroids (tapered gradually until eventual discontinuation). Each patient's immune status is very difficult to properly characterize at any sequential time point. Moreover, the association between immunosuppression and clinical outcomes following non-opportunistic infections remains doubtful [13]. Additionally, how clinicians adjust immunosuppressive regimens once there is an infection varies widely [14]. Therefore, it remains unclear how the immune status of these patients may have influenced CRE colonization and infection rates.

Finally, we found that neither CRE colonization nor infection was associated with graft failure within 1 year of index LT. While some studies have reported CRE infection to be associated with higher mortality, the impact of CRE colonization on mortality remains unclear [6, 15]. We speculate that lower rates of both CRE colonization and infection in our cohort may have contributed to the lack of an independent association between these factors and graft failure (an outcome more frequent than mortality). As our sample seemed somewhat comparable to other LT cohorts, in terms of demography, liver disease etiologies and severity, comorbidities, and risk factors for MDR colonization or infection, other factors may have influenced our CRE colonization and infection prevalence. For example, we speculate that our own locally implemented CRE surveillance program, in combination with enforced antibiotic stewardship and infection management protocols, may have helped reduce CRE colonization and infection prevalence and its impact on graft failure.

Limitations, Strengths, and Future Directions

Our results need to be interpreted in the context of the following limitations. First, this was a Southern European single-center observational cohort study, therefore prone

to selection bias. However, our consecutive enrollment of patients, with specific inclusion and exclusion criteria, may have helped to minimize such bias and strengthen the study's internal validity. Second, we could not capture data on pre-LT immunosuppressive medication use or on the prescription of antimicrobials during the post-LT period, including transplant-related prophylaxis. Such data could have provided more insights regarding the risk factors for CRE colonization and infection in this context. Third, the study was designed to assess the impact of CRE colonization and infection on graft failure. Thus, while we can speculate about how our CRE surveillance program may have impacted CRE colonization and infection prevalence, this was not actually the purpose of our study [16].

Despite these limitations, our study adds to the literature by documenting the recent CRE colonization and infection prevalence and its impact on clinical outcomes among Portuguese LT recipients in the context of an operational CRE surveillance program. Further studies from other jurisdictions could improve knowledge on the evolving CRE epidemiology and how it affects LT recipients' outcomes [17, 18]. Moreover, further studies dedicated to how CRE colonization and infection affect clinical outcomes may help establish specific thresholds to locally adjust LT-related antimicrobial prophylaxis and CRE infection empirical therapy [19, 20]. Finally, further studies are needed to test how different digestive decontamination strategies could potentially modify gut dysbiosis, CRE colonization and infection prevalence, and clinical outcomes post-LT [21].

Acknowledgments

We thank the clinical staff caring for liver transplant recipients.

Statement of Ethics

Study approval statement: The Central Lisbon University Hospital Center (CLUHC) Ethics Committee approved the study's protocol (INV_447).

Consent to participate statement: The Central Lisbon University Hospital Center (CLUHC) Ethics Committee waived the individual informed consent due to its observational character (INV_447).

Conflict of Interest Statement

The authors have no conflicts of interest to declare.

Funding Sources

This study was not supported by any sponsor or funder.

Author Contributions

Filipe S. Cardoso conceived the idea and wrote the protocol. João Caria, Ana C. Gonçalves, Gonçalo Cristóvão, Maria Carlos, Sara Magalhães, Vasco Almeida, and Filipe S. Cardoso

retrieved the data. João Caria and Filipe S. Cardoso performed the statistical analysis and wrote the manuscript. All authors provided content expertise and revised and approved the final manuscript.

Data Availability Statement

Data may be available upon reasonable request directed at the corresponding author.

References

- 1 Baganate F, Beal EW, Tumin D, Azoulay D, Mumtaz K, Black SM, et al. Early mortality after liver transplantation: defining the course and the cause. *Surgery*. 2018;164(4):694–704. <https://doi.org/10.1016/j.surg.2018.04.039>
- 2 Hand J, Patel G. Multidrug-resistant organisms in liver transplant: mitigating risk and managing infections. *Liver Transpl*. 2016;22(8):1143–53. <https://doi.org/10.1002/lt.24486>
- 3 Annavaiah MK, Gomez-Simmonds A, Macesic N, Sullivan SB, Kress A, Khan SD, et al. Colonizing multidrug-resistant bacteria and the longitudinal evolution of the intestinal microbiome after liver transplantation. *Nat Commun*. 2019;10(1):4715. <https://doi.org/10.1038/s41467-019-12633-4>
- 4 Chang FY, Singh N, Gayowski T, Drenning SD, Wagener MM, Marino IR. Staphylococcus aureus nasal colonization and association with infections in liver transplant recipients. *Transplantation*. 1998;65(9):1169–72. <https://doi.org/10.1097/00007890-199805150-00004>
- 5 Chiang D, Dingle TC, Belga S, Kabbani D, Bhanji RA, Walter J, et al. Association between gut colonization of vancomycin-resistant enterococci and liver transplant outcomes. *Transpl Infect Dis*. 2022;24(3):e13821. <https://doi.org/10.1111/tid.13821>
- 6 Taimur S, Pouch SM, Zubizarreta N, Mazumdar M, Rana M, Patel G, et al. Impact of pre-transplant carbapenem-resistant Enterobacteriales colonization and/or infection on solid organ transplant outcomes. *Clin Transplant*. 2021;35(4):e14239. <https://doi.org/10.1111/ctr.14239>
- 7 Giannella M, Bartoletti M, Campoli C, Rinaldi M, Coladonato S, Pascale R, et al. The impact of carbapenemase-producing Enterobacteriaceae colonization on infection risk after liver transplantation: a prospective observational cohort study. *Clin Microbiol Infect*. 2019;25(12):1525–31. <https://doi.org/10.1016/j.cmi.2019.04.014>
- 8 Wilson CB. An updated Declaration of Helsinki will provide more protection. *Nat Med*. 2013;19(6):664. <https://doi.org/10.1038/nm0613-664>
- 9 von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP, et al. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. *Int J Surg*. 2014;12(12):1495–9. <https://doi.org/10.1016/j.ijsu.2014.07.013>
- 10 Diene SM, Rolain JM. Carbapenemase genes and genetic platforms in Gram-negative bacilli: Enterobacteriaceae, Pseudomonas and Acinetobacter species. *Clin Microbiol Infect*. 2014;20(9):831–8. <https://doi.org/10.1111/1469-0691.12655>
- 11 Logan LK, Weinstein RA. The epidemiology of carbapenem-resistant Enterobacteriaceae: the impact and evolution of a global menace. *J Infect Dis*. 2017;215(Suppl 1_1):S28–36. <https://doi.org/10.1093/infdis/jiw282>
- 12 Macesic N, Gomez-Simmonds A, Sullivan SB, Giddins MJ, Ferguson SA, Korakavi G, et al. Genomic surveillance reveals diversity of multidrug-resistant organism colonization and infection: a prospective cohort study in liver transplant recipients. *Clin Infect Dis*. 2018;67(6):905–12. <https://doi.org/10.1093/cid/ciy199>
- 13 Vaidie J, Peju E, Jandeaux LM, Lesouhaitier M, Lacherade JC, Guillon A, et al. Long-term immunosuppressive treatment is not associated with worse outcome in patients hospitalized in the intensive care unit for septic shock: the PACIFIC study. *Crit Care*. 2023; 27(1):340. <https://doi.org/10.1186/s13054-023-04626-z>
- 14 Shepshelovich D, Tau N, Green H, Rozen-Zvi B, Issaschar A, Falcone M, et al. Immunosuppression reduction in liver and kidney transplant recipients with suspected bacterial infection: a multinational survey. *Transpl Infect Dis*. 2019;21(5):e13134. <https://doi.org/10.1111/tid.13134>
- 15 Lemos GT, Terrabuio DRB, Nunes NN, Song ATW, Oshiro ICV, D'Albuquerque LAC, et al. Pre-transplant multidrug-resistant infections in liver transplant recipients: epidemiology and impact on transplantation outcome. *Clin Transplant*. 2024;38(1):e15173. <https://doi.org/10.1111/ctr.15173>
- 16 Mularoni A, Martucci G, Douradinha B, Campanella O, Hazen B, Medaglia A, et al. Epidemiology and successful containment of a carbapenem-resistant Enterobacteriaceae outbreak in a southern Italian transplant institute. *Transpl Infect Dis*. 2019;21(4):e13119. <https://doi.org/10.1111/tid.13119>
- 17 Chan JL, Nazarian E, Musser KA, Snaveley EA, Fung M, Doernberg SB, et al. Prevalence of carbapenemase-producing organisms among hospitalized solid organ transplant recipients, five US hospitals, 2019–2020. *Transpl Infect Dis*. 2022;24(2):e13785. <https://doi.org/10.1111/tid.13785>
- 18 Pérez-Nadales E, Fernández-Ruiz M, Natera AM, Gutiérrez-Gutiérrez B, Mularoni A, Russelli G, et al. Efficacy of ceftazidime-avibactam in solid organ transplant recipients with bloodstream infections caused by carbapenemase-producing Klebsiella pneumoniae. *Am J Transplant*. 2023;23(7):1022–34. <https://doi.org/10.1016/j.ajt.2023.03.011>
- 19 Temkin E, Margalit I, Nutman A, Carmeli Y. Surgical antibiotic prophylaxis in patients colonized with multidrug-resistant Gram-negative bacteria: practical and conceptual aspects. *J Antimicrob Chemother*. 2021; 76(Suppl 1):i40–6. <https://doi.org/10.1093/jac/dkaa496>
- 20 Righi E, Muters NT, Guirao X, Del Toro MD, Eckmann C, Friedrich AW, et al. ESCMID/EUCIC clinical practice guidelines on perioperative antibiotic prophylaxis in patients colonized by multidrug-resistant Gram-negative bacteria before surgery. *Clin Microbiol Infect*. 2023;29(4):463–79. <https://doi.org/10.1016/j.cmi.2022.12.012>
- 21 Tacconelli E, Mazzaferri F, de Smet AM, Bragantini D, Eggimann P, Huttner BD, et al. ESCMID-EUCIC clinical guidelines on decolonization of multidrug-resistant Gram-negative bacteria carriers. *Clin Microbiol Infect*. 2019;25(7):807–17. <https://doi.org/10.1016/j.cmi.2019.01.005>